Oestrogen attenuates coronary vasoconstriction after angioplasty: role of endothelin-1

What Was Tested

The paper reports a study of Endothelin-1, published as a clinical trial.

There were controversies as to whether endothelin-1 is released after coronary angioplasty.

Who Took Part

The abstract describes 24 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

The study was designed to prospectively investigate 24 consecutive patients scheduled for elective coronary angioplasty.

Patients were randomized into two groups according to whether they did not (group 1, n = 12) or did (group 2, n = 12) have intracoronary treatment with oestrogen.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Endothelin-1 group and the comparison group should start out alike.

Quantitative coronary angiography was monitored at baseline, immediately after successful angioplasty, and 15 min after the last deflation.

Blood samples for measuring the levels of endothelin-1 were drawn from the ascending aorta and the coronary sinus simultaneously before angioplasty and 15 min after balloon dilatation.

What Was Measured

The subject headings attached to it are Angioplasty, Balloon, Coronary, Aorta, Blood Pressure, Coronary Artery Disease, Coronary Vessels, Electrocardiography and Endothelin-1.

What This Means in Plain Language

The paper is a randomized study of Endothelin-1 in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (European journal of clinical investigation), a journal based in England.

More context: the Endothelin-1 compound page, all human trials.